Artiva Biotherapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
ARTV$4.22+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
(in thousands, except share and par value data)
| AS OF | ||
|---|---|---|
| DECEMBER 31,2024 | DECEMBER 31,2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $40,235 | $53,504 |
| Short-term investments | 145,193 | 23,467 |
| Accounts receivable (including related party amounts of $0 and $569, respectively) | — | 1,034 |
| Other receivables (including related party amounts of $0 and $607, respectively) | 146 | 724 |
| Prepaid expenses and other current assets | 3,057 | 1,092 |
| Total current assets | 188,631 | 79,821 |
| Restricted cash | 258 | 258 |
| Property and equipment, net | 6,370 | 8,096 |
| Operating lease right-of-use assets | 13,794 | 16,547 |
| Financing lease right-of-use asset | 261 | — |
| Other long-term assets | 267 | 392 |
| Total assets | $209,581 | $105,114 |
| Liabilities, convertible preferred stock, and stockholders’ equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable (including related party amounts of $276 and $199, respectively) | $1,121 | $614 |
| Accrued expenses (including related party amounts of $713 and $2,161, respectively) | 7,392 | 8,017 |
| Current portion of operating lease liabilities | 3,618 | 3,596 |
| Current portion of financing lease liability | 122 | — |
| Total current liabilities | 12,253 | 12,227 |
| Operating lease liabilities, net of current portion | 10,570 | 13,316 |
| Financing lease liability, net of current portion | 44 | — |
| Simple agreements for future equity (“SAFEs”) (including related party amounts of $0 and $20,315, respectively) | — | 25,100 |
| Other non-current liabilities | 73 | 73 |
| Total liabilities | 22,940 | 50,716 |
| Commitments and contingencies (Note 11) | ||
| Series A convertible preferred stock, $0.0001 par value; zero and 16,110,463 shares authorized as of December 31, 2024 and December 31, 2023, respectively; zero and 3,673,148 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively; zero and $80,552 aggregate liquidation preference at December 31, 2024 and December 31, 2023, respectively | — | 96,767 |
| Series B convertible preferred stock, $0.0001 par value; zero and 10,909,091 shares authorized as of December 31, 2024 and December 31, 2023, respectively; zero and 2,487,237 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively; zero and $120,000 aggregate liquidation preference at December 31, 2024 and December 31, 2023, respectively | — | 119,646 |
| Stockholders’ equity (deficit): | ||
| Preferred stock, $0.0001 par value; 10,000,000 and zero shares authorized at December 31, 2024 and December 31, 2023 respectively; zero shares issued and outstanding as of December 31, 2024 and December 31, 2023 | — | — |
| Common stock, $0.0001 par value; 700,000,000 and 38,998,588 shares authorized at December 31, 2024 and December 31, 2023, respectively; 24,291,607 and 809,758 shares issued and outstanding at December 31, 2024 and December 31, 2023 | 3 | — |
| Additional paid-in capital | 433,451 | 18,988 |
| Accumulated other comprehensive gain (loss) | (129) | 308 |
| Accumulated deficit | (246,684) | (181,311) |
| Total stockholders’ equity (deficit) | 186,641 | (162,015) |
| Total liabilities, convertible preferred stock and stockholders’ equity (deficit) | $209,581 | $105,114 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.